Core Insights - The article discusses a strategy to create a diversified 10-stock REIT portfolio aimed at retirement, focusing on REITs trading at a discount across various property sectors [1] Group 1: Selected REITs - The first three REITs highlighted for the portfolio are Sun Communities (SUI), Crown Castle (CCI), and VICI Properties (VICI), which are diversified across manufactured housing, cell towers, and gaming sectors [1] - The next three REITs to be included will focus on industrial, healthcare, and net lease sectors to further enhance diversification and reduce portfolio volatility [1] Group 2: Rexford Industrial (REXR) - REXR owns 422 properties in Southern California, which has the lowest industrial vacancy rate at 3.9% compared to the national average of 6.1% [2] - The diversified portfolio includes warehousing/transportation (31%), wholesale trade (23%), manufacturing (23%), and other sectors [2] - In Q2-24, REXR reported FFO of $0.60 per share, an 11% year-over-year growth, with same-property NOI growth of 9.1% [3] - The company has $229 million of incremental cash NOI growth expected over the next three years [3] - REXR has a net debt to EBITDA ratio of 4.6x and nearly $2 billion in total liquidity [3] - The stock trades at $50.92 with a P/AFFO multiple of 27.7x, and a dividend yield of 3.3% [3] Group 3: Healthpeak Properties (DOC) - DOC specializes in healthcare real estate with a market cap of $15.4 billion, focusing on life science labs, outpatient medical, and continuing care retirement communities [4] - The lab properties segment accounts for 51.3% of adjusted NOI, while outpatient medical makes up 37.6% [4] - In Q2-24, DOC reported FFO of $0.45 per share and increased its FFO guidance range to $1.77-$1.81 [4] - The stock trades at $22.28 with a P/AFFO multiple of 14.4x and a dividend yield of 5.4% [4] Group 4: Realty Income (O) - O is a net lease REIT with over 15,500 properties across the U.S. and Europe, benefiting from scale advantages in M&A and bulk transactions [6][7] - The company has a net debt to annualized Pro Forma Adj EBITDA of 5.3x and a fixed charge coverage ratio of 4.6x [7] - In Q2-24, O reiterated full-year investments at $3 billion and an AFFO per share guidance of $4.15 to $4.21 [7] - The stock trades at $62.11 with a P/AFFO multiple of 15.1x and a dividend yield of 5.1% [7] Group 5: Summary of REITs - A summary table of the six REITs includes their price, P/AFFO, normal P/AFFO, variance, and dividend yield, indicating that all selected REITs are trading below their normal P/AFFO ranges [8] - The average P/AFFO across the selected REITs is 18.2, with an average dividend yield of 4.5% [8]

Healthpeak Properties, Inc. (DOC) is well-poised to benefit from its diversified and top-quality healthcare real estate assets in the high barrier-to-entry markets of the United States. Solid demand for lab assets is likely to drive its lab portfolio's growth. Its continuing care retirement community (CCRC) portfolio is poised to gain from the rise in senior citizens' healthcare expenditure. A healthy balance sheet position augurs well. Shares of this Zacks Rank #2 (Buy) company have rallied 36.7% over the ...

Healthpeak (DOC) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. The power of ...

akinbostanci The Federal Reserve opted to keep interest rates steady at about 5.3%. This means that all eyes are on September 18th when they will once again vote on interest rates. It's now widely expected that rates will be cut then and likely a second or even third cut by the end of this year. Many REITs have commenced a rally anticipating a rate cut. However, we believe that there is plenty of room to run for REIT's as shares remain undervalued. Brad Thomas ✿ @rbradthomas · 2h $IRET +9.9% vs $VNQ +3.7% ( ...

Healthpeak Properties, Inc. (DOC) reported second-quarter 2024 funds from operations (FFO) as adjusted per share of 45 cents, beating the Zacks Consensus Estimate by a penny. The reported figure remained unchanged from the prior-year quarter. Behind the Headlines During the reported quarter, Healthpeak executed lab new and renewal leases totaling 797,000 square feet. For the outpatient medical portfolio, new and renewal leases aggregated 905,000 square feet. Dividend Update Healthpeak revised its guidance f ...

Financial Data and Key Metrics Changes - The company reported FFO as adjusted of $0.45 per share and AFFO of $0.39 per share, with total portfolio same-store growth of 4.5% [96] - The net debt to EBITDA ratio ended the quarter at 5.2 times, with nearly $3 billion of liquidity available [98] - Year-to-date, the company repurchased $188 million of stock at a blended price of just under $18 per share, equating to an implied cap rate in the high 7% range [91] Business Line Data and Key Metrics Changes - In the life science business, the company signed 800,000 square feet of leases in Q2, with 75% being renewals and 25% new leases, achieving a positive releasing spread of 6% [82] - The outpatient medical business saw occupancy increase by 20 basis points and re-leasing spreads were positive at 4.7% [85] - The same-store growth for CCRCs was reported at 2%, driven by occupancy growth and strong rate growth of 7% [104] Market Data and Key Metrics Changes - The leasing pipeline remains strong, with 620,000 square feet under signed LOI, including significant projects like Vantage, Portside, and Directors Gateway [84] - The company noted that more than half of the LOI pipeline is new leasing on currently vacant space, indicating potential for future growth [41] - The market for outpatient medical asset sales was characterized by a blended cap rate of 6.8% for recent transactions [89] Company Strategy and Development Direction - The company is focused on enhancing its relationships within the healthcare ecosystem, with 70% of its team now directly supporting real estate, up from less than 50% two years ago [80] - The strategy includes fine-tuning the portfolio through opportunistic asset sales, which are expected to be accretive to future growth [60] - The company plans to continue pursuing new development opportunities in core markets, with a projected outpatient medical development pipeline of $500 million to $1 billion over the next few years [33] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the leasing environment, noting that tenants are becoming more comfortable making real estate decisions, which has led to a strong leasing quarter [81] - The company anticipates a strong Q3, with additional leases signed in July and a robust pipeline indicating continued demand [84] - Management highlighted the importance of capital raising in the biopharma sector as a positive indicator for future leasing activity [17] Other Important Information - The company executed early renewals across its portfolio, extending the blended maturity date to December 2035, with a blended re-leasing spread of 13% [87] - The company has significant dry powder for future growth, with plans for acquisitions, redevelopments, and stock buybacks [105] - The merger integration is progressing well, with year one synergies tracking higher than $45 million [78] Q&A Session Summary Question: What explains the behavioral switch on the life science space with tenants starting to think more constructively about doing deals? - Management noted that strong capital raising in the biopharma sector has positively influenced tenant leasing decisions, with the first half of the year being the strongest since 2021 [17] Question: Can you quantify how much you can grow the outpatient medical development pipeline over the next few years? - Management indicated that the outpatient medical development pipeline could grow substantially, estimating $500 million to $1 billion over the next few years [33] Question: What is the rationale behind the seller financing for asset sales? - The rationale for seller financing was to ensure certainty of execution in a volatile market, allowing the company to close transactions without retreating on price [26] Question: How much of the LOI pipeline is related to existing tenants versus new tenants? - More than half of the LOI pipeline is new leasing on currently vacant space, indicating significant upside potential [41] Question: What types of tenant activity are being seen on the new leasing side? - The company is capturing market share, with leasing activity primarily tied to companies that have successfully raised capital, including both existing tenants and new tenants [120]

The reported revenue compares to the Zacks Consensus Estimate of $660.55 million, representing a surprise of +5.29%. The company delivered an EPS surprise of +2.27%, with the consensus EPS estimate being $0.44. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. View all Key Company Metrics for Healthpeak here>>> Healthpeak ...

Healthpeak (DOC) came out with quarterly funds from operations (FFO) of $0.45 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to FFO of $0.45 per share a year ago. These figures are adjusted for non-recurring items. Over the last four quarters, the company has surpassed consensus FFO estimates four times. The sustainability of the stock's immediate price movement based on the recently-released numbers and future FFO expectations will mostly depend on management's commentary ...

Core Viewpoint - Healthpeak (NYSE:DOC) is viewed as a solid investment opportunity, particularly for those who invested below $17/share, as the current share price exceeds $20/share, indicating a significant appreciation in value [2][8][9]. Investment Thesis - The company has a diverse portfolio that includes life science properties, outpatient medical care facilities, and continuing care retirement communities, which positions it well within the healthcare REIT sector [2][9]. - Healthpeak is characterized as a yield/income-oriented investment with potential for capital appreciation, rather than a high-growth investment [4][9]. - The company has a conservative financial structure, with low leverage (less than 5.3x net debt/EBITDA) and no maturities due in 2024, which enhances its stability [5][9]. Market Position and Performance - Healthpeak has executed leases in 2023 that exceeded original expectations, particularly in the outpatient and lab segments, contributing to its strong market position [5][6]. - The occupancy rates for outpatient medical facilities have increased by over 200 basis points since COVID-19, indicating a recovery and growth in demand [6]. - The company has a significant presence in high-growth markets, with relationships with top health systems, which supports its revenue generation [6][7]. Valuation and Future Outlook - The current price-to-FFO (Funds From Operations) ratio is considered reasonable, with a long-term price target of $27/share, suggesting a conservative upside of 10-12% [9]. - Despite the recent price increase, the company is still viewed as a "BUY" for investors who are willing to enter at current levels, although caution is advised regarding valuation [8][9]. - The overall outlook for Healthpeak remains positive, with expectations of stable results and slight growth in the coming years, despite challenges in the broader REIT sector [9].

Healthpeak Properties, Inc. (DOC) is well-poised to benefit from its diversified and top-quality healthcare real estate assets in the high barrier-to-entry markets of the United States. Solid demand for lab assets amid the increasing need for drug innovation and developments is likely to drive its lab portfolio's growth. Its continuing care retirement community (CCRC) portfolio is poised to gain from the rise in senior citizens' healthcare expenditure. However, competition from industry players and a high i ...